Hyperfine Inc (HYPR)
$0.81
Insights on Hyperfine Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 2.33M → 2.68M (in $), with an average increase of 13.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -10.75M → -10.68M (in $), with an average increase of 0.7% per quarter
Vs BSX
In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 65.8%
Vs BSX
In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 157.1%
Performance
- $0.80$0.95$0.81
1.23%
Downside
Day's Volatility :15.79%
Upside
14.74%
- $0.81$3.28$0.81
0.0%
Downside
52 Weeks Volatility :75.3%
Upside
75.3%
Returns
| Period | Hyperfine Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -5.21% | -0.7% | 0.0% |
6 Months | -51.85% | 6.6% | 0.0% |
1 Year | -34.06% | 3.7% | -1.5% |
3 Years | -90.88% | 14.0% | -21.8% |
Highlights
Market Capitalization | 71.2M |
Book Value | $1.17 |
Earnings Per Share (EPS) | -0.62 |
Wall Street Target Price | 1.3 |
Profit Margin | 0.0% |
Operating Margin TTM | -432.95% |
Return On Assets TTM | -26.35% |
Return On Equity TTM | -42.51% |
Revenue TTM | 11.0M |
Revenue Per Share TTM | 0.16 |
Quarterly Revenue Growth YOY | 88.6% |
Gross Profit TTM | 907.0K |
EBITDA | -47.1M |
Diluted Eps TTM | -0.62 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.54 |
EPS Estimate Next Year | -0.5 |
EPS Estimate Current Quarter | -0.18 |
EPS Estimate Next Quarter | -0.15 |
Analyst Recommendation
Analyst Forecast
What analysts predicted
Upside of 60.49%
Technicals Summary
Sell
Neutral
Buy
Hyperfine Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Hyperfine Inc | -23.53% | -51.85% | -34.06% | -90.88% | -90.91% |
 Stryker Corporation | -5.1% | 24.37% | 15.51% | 30.88% | 86.41% |
 Boston Scientific Corp. | 1.07% | 34.02% | 31.68% | 66.24% | 93.56% |
 Edwards Lifesciences Corp. | -6.04% | 25.15% | 3.43% | -1.49% | 47.65% |
 Abbott Laboratories | -5.82% | 10.82% | 1.68% | -14.96% | 43.26% |
 Medtronic Plc | -5.47% | 8.78% | -3.15% | -37.3% | -6.1% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Hyperfine Inc | NA | NA | NA | -0.54 | -0.43 | -0.26 | NA | 1.17 |
Stryker Corporation | 40.98 | 40.98 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 63.66 | 63.66 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 39.15 | 39.15 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 11.06 |
Abbott Laboratories | 33.4 | 33.4 | 5.99 | 4.59 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.16 | 25.16 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Hyperfine Inc | NA | $71.2M | -90.91% | NA | 0.0% |
Stryker Corporation | Buy | $128.5B | 86.41% | 40.98 | 15.44% |
Boston Scientific Corp. | Buy | $100.1B | 93.56% | 63.66 | 11.18% |
Edwards Lifesciences Corp. | Buy | $54.2B | 47.65% | 39.15 | 23.36% |
Abbott Laboratories | Buy | $189.5B | 43.26% | 33.4 | 14.27% |
Medtronic Plc | Buy | $105.2B | -6.1% | 25.16 | 13.0% |
Institutional Holdings
Vanguard Group Inc
4.41%Fosun International Ltd
2.42%Avidity Partners Management LP
1.65%Alphabet Inc
1.25%BlackRock Inc
0.97%Geode Capital Management, LLC
0.67%
Corporate Announcements
Hyperfine Inc Earnings
Hyperfine Inc’s price-to-earnings ratio stands at None
Read More
Company Information
hyperfine’s mission is to make mri accessible to every patient, regardless of income or resources. anytime. anywhere.hyperfine’s swoop® portable mr imaging system™ addresses limitations of current imaging technologies. swoop wheels directly to a patient’s bedside, where it plugs into a standard electrical outlet and uses an apple ipad® for control. images display within minutes, enabling critical decision-making capabilities across various clinical settings such as neurointensive care units, emergency departments, pediatrics, and more. designed as a complementary system to fixed conventional mri systems, new users can be trained on system operation, device navigation, and safety in about 30 minutes, helping clinicians streamline workflow. the complete swoop™ portable mr imaging system costs less than the annual service contract for most fixed conventional mri systems.in august 2020, swoop received market-ready fda clearance for portable mr imaging of the brain and head for patients of
Organization | Hyperfine Inc |
Employees | 131 |
CEO | Mr. R. Scott Huennekens CPA, M.B.A. |
Industry | Healthcare |
